Share This Page
LYSODREN Drug Patent Profile
✉ Email this page to a colleague
US Patents and Regulatory Information for LYSODREN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esteve | LYSODREN | mitotane | TABLET;ORAL | 016885-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
LYSODREN (mitotane): Investment Scenario and Fundamentals Analysis
What is LYSODREN and what is it used for?
LYSODREN is the brand for mitotane, an adrenolytic drug used in the management of adrenocortical carcinoma (ACC). In practice, its investment relevance is tied to (1) how ACC incidence and treatable patient populations trend, (2) whether mitotane remains standard-of-care in major geographies, (3) competition from other ACC regimens, and (4) any pricing and distribution changes that affect realized net sales.
Core commercial profile
- Indication: adrenocortical carcinoma (ACC)
- Mechanism: adrenolytic activity (class-specific; no direct 1:1 alternative with identical pharmacology)
- Administration reality: chronic use patterns with long-tail dosing in suitable patients (creates a “therapy-duration” component to revenue)
How does the product map to an investment thesis?
A defensible investment thesis for LYSODREN typically anchors on three value drivers and three risks.
Value drivers
- Specialty, entrenched use in ACC
- Mitotane has durable clinical positioning in ACC regimens in many markets because it is a long-established therapy and is supported by ACC treatment paradigms used by specialist oncology/endocrinology networks.
- Limited direct substitution
- ACC regimens use multiple agents, but mitotane does not face a straightforward branded “drop-in” equivalent in standard practice.
- Potential pricing power in a rare/complex cancer
- Where coverage and formularies treat mitotane as a specialty cornerstone, realized price can hold better than broad oncology drugs.
Key risks
- Clinical substitution by combination standards
- Newer ACC protocols can shift prescribing away from mitotane or reduce use duration, especially if efficacy endpoints are met by alternative approaches.
- Supply, manufacturing, and distribution friction
- Specialty generics or supply issues can affect continuity, which matters for chronic dosing.
- Reimbursement pressure
- ACC is rare; payer lists can change quickly when cost-effectiveness narratives evolve.
What are the fundamentals investors focus on for mitotane?
A fundamentals model should track LYSODREN performance through four levers.
1) Market access and pricing
- Realized net price versus list price (rebates, discounts, copay support if applicable)
- Formulary position by geography (hospital and payer)
- Utilization controls (prior authorization, step edits)
Investment implication: For rare oncology brands, the business risk is often less about demand collapse and more about margin compression via contracting and access redesign.
2) Prescription demand drivers
- ACC incidence and diagnosis rate
- Stage at presentation (later stage increases need for systemic therapy)
- Treatment continuity (dose stability and adherence)
- Physician behavior (specialist centers treat more consistently)
Investment implication: Mitotane demand tends to correlate with the number of patients who are treated and remain on therapy long enough to complete clinically meaningful cycles.
3) Competitive intensity
- ACC regimen competition
- Multi-agent chemotherapy and newer targeted approaches can change “mix,” even if mitotane remains part of some regimens.
- Therapeutic duplication risk
- If a competitor achieves comparable outcomes with less monitoring burden, clinicians may shift.
Investment implication: The key variable is not the presence of competitors; it is whether they reduce the probability that mitotane is used at all (penetration) or reduce dose duration (intensity).
4) Safety and monitoring burden
Mitotane’s use is constrained by monitoring requirements and tolerability. That can drive:
- Discontinuation rates
- Dose reductions
- Switching to alternative regimens
Investment implication: Safety management can cap “maximum reachable utilization,” even in supportive coverage environments.
What does an investment scenario look like under realistic market dynamics?
Below is a scenario structure that maps to typical risk-adjusted underwriting logic for a specialty oncology drug.
Scenario A: Base case (steady utilization, moderate margin pressure)
- Utilization: stable ACC-treated population share on mitotane
- Pricing: modest net price erosion from contracting
- Mix: gradual shift in regimen composition but mitotane remains a standard component
- Outcome: revenue stability with margin compression risk
Scenario B: Upside (stable or improved penetration, limited access disruption)
- Utilization: mitigation of regimen substitution via clinical reaffirmation or guideline support
- Pricing: stable net price due to durable formulary positioning
- Outcome: revenue growth driven by patient volume and better persistence
Scenario C: Downside (penetration erosion or duration reduction)
- Utilization: increased regimen substitution reduces mitotane “on-therapy probability”
- Pricing: accelerated payer contracting pressure
- Outcome: volume-led revenue decline and margin compression
What to watch in each scenario
- Guideline updates for ACC treatment that mention or downplay mitotane
- Payer formulary changes in high-spend geographies
- Evidence of alternative regimens improving outcomes in ways that reduce mitotane reliance
- Any supply chain changes that impact continuity
How should investors diligence LYSODREN’s patent and market exclusivity posture?
Investment-grade diligence requires pinning:
- Active exclusivity constraints (if any remain for brand formulation, method-of-use, or controlled distribution)
- Generic entry risk (if brand exclusivity is exhausted)
- Data exclusivity and pediatric exclusivity relevance (where applicable)
- Life-cycle events that can drive step-function margin changes (generic launch, settlement, switching)
Commercial implication: For specialty oncology, the valuation sensitivity often spikes around expected generic competition windows and around any litigation settlement terms that shift entry timing.
What operational and distribution signals matter?
Investors should treat distribution continuity as a financial variable.
Signals to monitor
- Quarterly supply continuity (backorders, fulfillment delays, allocation)
- Wholesale inventory trends (risk of channel overhang)
- Channel demand indicators (specialty pharmacy activity, hospital dispensing patterns)
Why it matters: In chronic oncology therapy, fulfillment disruption can turn into permanent prescribing behavior change, even after supply normalizes.
How does LYSODREN compete in ACC treatment pathways?
Mitotane competes within a care pathway rather than as a single-agent across every ACC patient. The decision node is:
- Which patients get mitotane
- When they get it (front-line vs subsequent lines)
- How long they stay on it
Practical competitive lens
- Regimen positioning: whether mitotane is used alone or combined
- Monitoring trade-offs: whether patients tolerate and continue
- Therapy sequencing: whether newer protocols displace mitotane use early
Investment implication: Even if overall ACC drug spend grows, mitotane can lose share if it is displaced earlier in care.
What are the concrete diligence checkpoints for an investment committee?
Use these checkpoints as pass/fail items.
Diligence Checklist
- Guideline and consensus mapping: presence and role of mitotane in current ACC treatment guidance by major regions
- Patient pathway mapping: proportion of ACC patients expected to receive mitotane and expected persistence
- Contracting and access review: net price trajectory and payer exceptions
- Channel inventory health: signs of demand absorption versus channel stocking
- Regulatory and litigation timeline: any events that signal generic competition or exclusivity changes
KPI set
| KPI | What to measure | Why it matters for LYSODREN |
|---|---|---|
| Realized net sales per quarter | Net price and volume | Specialty margin and durability |
| Prescription volume / patient starts | Starts, not just refills | Captures penetration changes |
| Persistence / discontinuation proxy | Time on therapy | Detects regimen displacement risk |
| Gross-to-net movement | Rebates, chargebacks | Reveals access pressure early |
| Supply continuity metrics | backorder/lead-time | Prevents demand loss due to disruption |
Key Takeaways
- LYSODREN is mitotane for adrenocortical carcinoma, a specialty oncology product where utilization persistence and care-pathway positioning drive revenue more than short-term market sentiment.
- The investment case is most sensitive to whether treatment pathways still include mitotane early and for long enough to sustain persistence.
- The highest practical underwriting risks are access margin compression, penetration erosion from evolving ACC regimens, and supply or distribution friction.
- A scenario model with stable, upside, and downside penetration and persistence is the correct structure for risk-adjusted decisions.
FAQs
-
Is LYSODREN a growth driver or a durability play?
It is generally underwritten as a durability play in ACC because demand tracks specialized care pathways and persistence more than broad market uptake. -
What matters most for forecasting mitotane revenue?
Treatment penetration (patient starts) and persistence (time on therapy), plus realized net price from contracting. -
Does ACC regimen competition automatically reduce LYSODREN sales?
Not automatically. It reduces sales when it changes sequencing or reduces the probability that patients receive mitotane. -
What operational factors can harm revenue even if demand exists?
Supply continuity issues that disrupt dispensing and cause permanent prescribing behavior changes. -
Where do margin risks typically come from for specialty oncology drugs?
Gross-to-net movement driven by payer contracting, rebates, and chargebacks.
References
[1] FDA. LYSODREN (mitotane) prescribing information. (Accessed via FDA label repository).
[2] National Cancer Institute. Adrenocortical carcinoma treatment (PDQ). (Content updated periodically).
[3] EMA. LYSODREN (mitotane) product information. (Accessed via EMA/European public assessment resources).
More… ↓
